uk
us
de
Scibase
  • APPLICATIONS
    • MELANOMA
    • KERATINOCYTE CANCER
    • BARRIER RESEARCH
  • EIS TECHNOLOGY
    • HOW TO MEASURE
    • CLINICAL STUDIES
    • PUBLICATIONS
    • RESEARCH MILESTONES
  • FOR PATIENTS
    • SKIN CANCER INFORMATION
    • WHY NEVISENSE?
    • FIND CLINICS
    • SELF EXAMINATION
    • PATIENT ORGANIZATIONS
  • SCIBASE
    • ABOUT SCIBASE
    • AVAILABLE MARKETS
    • CAREERS
    • WE ARE SCIBASE
    • NEWS & EVENTS
    • CEO-LETTERS
    • AVAILABLE MATERIALS
    • FINANCIAL INFORMATION
    • CONTACT US
  • INVESTORS
  • CONTACT US
  • The Nevisense product
    • How it works
    • How to measure
    • The EIS Technology
    • Clinical studies
    • Clinical benefits
    • Publications
    • Patient lesion cards
    • Barrier Research
  • For patients
    • Barrier Function testing
    • Skin cancer information
    • Why Nevisense?
    • Find clinics
    • Self examination
    • Patient organizations
  • Scibase
    • About Scibase
    • Available materials
    • We are Scibase
    • News and events
    • Contact us
    • Privacy and Cookie policy
    • Login
  • Investors
    • About Scibase
    • Press releases
    • Business model
    • Reports and presentations
    • Corporate Governance
    • Contact
uk
us
de

Increased diagnostic accuracy in the detection of malignant melanoma, Keratinocyte cancer and other skin diseases

CEO-LETTERS

Simon Grant, CEO of Scibase, shares his knowledge and perspectives;

 

 

CEO Letter 9 – January 2022

CEO Letter 8 – September 2020

CEO Letter 7 – July 2020

CEO Letter 6 – May 2020

CEO Letter 5 – April 2019

CEO-letter 4  – November 2017

CEO-letter 3  – April 2017

CEO-letter 2  – January 2017

CEO-letter 1  – December 2016

CEO Letter 9

CEO-Letter 8

CEO-Letter 7

CEO-Letter 6

US progress and Nevisense Go

CEO-LETTER 5

7 April 2019 - Nevisense 3.0 and Skin Barrier application

CEO-LETTER 4

2 Nov 2017 - Updated strategy and securing our long-term capital needs

CEO-LETTER 3

April 2017 - Future trends and technologies

CEO-LETTER 2

January 2017 - Nevisense View: a new product with great potential

CEO-LETTER 1

December 2016: Teledermoscopy – good for increased awareness and access but is it good enough as a diagnostic method?

  • The Nevisense product
    • How it works
    • How to measure
    • The EIS Technology
    • Clinical studies
    • Clinical benefits
    • Publications
    • Patient lesion cards
    • Barrier Research
  • For patients
    • Barrier Function testing
    • Skin cancer information
    • Why Nevisense?
    • Find clinics
    • Self examination
    • Patient organizations
  • Scibase
    • About Scibase
    • Available materials
    • We are Scibase
    • News and events
    • Contact us
    • Privacy and Cookie policy
    • Login
  • Investors
    • About Scibase
    • Press releases
    • Business model
    • Reports and presentations
    • Corporate Governance
    • Contact